BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 20501841)

  • 1. The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-A blockade.
    Nisancioglu MH; Betsholtz C; Genové G
    Cancer Res; 2010 Jun; 70(12):5109-15. PubMed ID: 20501841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice.
    Bequet-Romero M; Ayala M; Acevedo BE; RodrĂ­guez EG; Ocejo OL; Torrens I; Gavilondo JV
    Angiogenesis; 2007; 10(1):23-34. PubMed ID: 17273909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
    Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.
    Holloway SE; Beck AW; Shivakumar L; Shih J; Fleming JB; Brekken RA
    Ann Surg Oncol; 2006 Aug; 13(8):1145-55. PubMed ID: 16791450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sprouty4 deficiency potentiates Ras-independent angiogenic signals and tumor growth.
    Taniguchi K; Ishizaki T; Ayada T; Sugiyama Y; Wakabayashi Y; Sekiya T; Nakagawa R; Yoshimura A
    Cancer Sci; 2009 Sep; 100(9):1648-54. PubMed ID: 19493272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What brings pericytes to tumor vessels?
    Jain RK; Booth MF
    J Clin Invest; 2003 Oct; 112(8):1134-6. PubMed ID: 14561696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antitumor effect of recombinant T7 phage vaccine expressing xenogenic vascular endothelial growth factor on Lewis lung cancer in mice].
    Li XH; Tang L; Liu D; Sun HM; Zhou CC; Tan LS; Wang LP; Zhang PD; Zhang SQ
    Ai Zheng; 2006 Oct; 25(10):1221-6. PubMed ID: 17059764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma.
    Lu C; Kamat AA; Lin YG; Merritt WM; Landen CN; Kim TJ; Spannuth W; Arumugam T; Han LY; Jennings NB; Logsdon C; Jaffe RB; Coleman RL; Sood AK
    Clin Cancer Res; 2007 Jul; 13(14):4209-17. PubMed ID: 17634550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S1P(2), the G protein-coupled receptor for sphingosine-1-phosphate, negatively regulates tumor angiogenesis and tumor growth in vivo in mice.
    Du W; Takuwa N; Yoshioka K; Okamoto Y; Gonda K; Sugihara K; Fukamizu A; Asano M; Takuwa Y
    Cancer Res; 2010 Jan; 70(2):772-81. PubMed ID: 20068174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene transfer of a soluble receptor of VEGF inhibits the growth of experimental eyelid malignant melanoma.
    Shiose S; Sakamoto T; Yoshikawa H; Hata Y; Kawano Y; Ishibashi T; Inomata H; Takayama K; Ueno H
    Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2395-403. PubMed ID: 10937546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
    Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo.
    Ueda Y; Yamagishi T; Ikeya H; Hirayama N; Itokawa T; Aozuka Y; Samata K; Nakaike S; Tanaka M; Ono M; Saiki I
    Anticancer Res; 2004; 24(5A):3009-17. PubMed ID: 15517909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumor vasculature with both cellular and humoral immunity.
    Chen XY; Zhang W; Zhang W; Wu S; Bi F; Su YJ; Tan XY; Liu JN; Zhang J
    Clin Cancer Res; 2006 Oct; 12(19):5834-40. PubMed ID: 17020991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway.
    Jung MH; Lee SH; Ahn EM; Lee YM
    Carcinogenesis; 2009 Apr; 30(4):655-61. PubMed ID: 19228635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of cyclooxygenase-2 disrupts tumor vascular mural cell recruitment and survival signaling.
    Lee A; Frischer J; Serur A; Huang J; Bae JO; Kornfield ZN; Eljuga L; Shawber CJ; Feirt N; Mansukhani M; Stempak D; Baruchel S; Glade Bender J; Kandel JJ; Yamashiro DJ
    Cancer Res; 2006 Apr; 66(8):4378-84. PubMed ID: 16618763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
    Fernando NT; Koch M; Rothrock C; Gollogly LK; D'Amore PA; Ryeom S; Yoon SS
    Clin Cancer Res; 2008 Mar; 14(5):1529-39. PubMed ID: 18316578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.
    Prewett M; Huber J; Li Y; Santiago A; O'Connor W; King K; Overholser J; Hooper A; Pytowski B; Witte L; Bohlen P; Hicklin DJ
    Cancer Res; 1999 Oct; 59(20):5209-18. PubMed ID: 10537299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.